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The fact that not everyone with Ebola virus
disease (EVD) has died during the ongo-
ing outbreak in West Africa, with an esti-
mated case fatality rate of 70.8% by Sep-
tember 2014 (1), suggests that some kind
of immunity to this virus is possible. If
left unchecked, this scenario will undoubt-
edly shift to a higher figure, as health-
care conditions in many of the countries
affected may not always enable infected
hosts to recover. Although gender differ-
ences in the survival, incidence, and/or
severity of infection are unknown, the
current Ebola virus outbreak represents
an unprecedented disaster for humans (1,
2) and a zoonotic successful strategy (3)
for a virus that cunningly and rapidly
hijacks innate immunity to devastating
effect. Human to human transmission is
via contact with bodily fluids from symp-
tomatic patients, which was identified in
the first epidemic almost 40 years ago, but
unlike prior epidemics, which consisted of
sporadic short periods of human trans-
mission, there is now a shift to a pro-
longed period of viral transmission (over
9 months at the time of writing). This
is, in part, a reflection of the movement
of people into urban densely populated
regions (2). In fact, there are distinct par-
allels between the first outbreak in the
Zaire with today’s outbreak – both being
caused by Zaire Ebolavirus (1, 4). Impor-
tantly, however, the current and ongoing
outbreak is occurring in this region for the
first time, and there are fears that without
blocking transmission, Ebola may become
endemic (2). What then are the medical
efforts under way to halt the spread of
Ebola with immune therapies and vaccine
strategies? Should we temper the usual sci-
entific rigor of clinical trials and roll-out
candidate vaccines and therapies directly
into people? How should the scientific, and
specifically the immunology community,
meet the rapidity of EVD spread, which
without doubt is the major challenge and
crisis of today.
Ebola, a filovirus, encodes seven genes:
nucleoprotein (NP), VP35 (polymerase
co-factor), VP40 (matrix protein), glyco-
protein (GP), VP30 (transcription activa-
tor), VP24 (secondary matrix protein), and
RNA-dependent RNA polymerase (5). The
most likely routes of Ebola entry into the
body are via mucosal surfaces, the conjunc-
tiva, the oropharynx, or injured skin routes
(6). From human and monkey studies, the
primary targets are dendritic cells, mono-
cytes, macrophages, and Kupffer cells in
the liver and entry mechanisms include the
GP interacting with an unidentified recep-
tor and inducing: (i) endocytosis medi-
ated by lipid rafts; (ii) macropinocyto-
sis; and (iii) clathrin-mediated transport
(5). Experimental models have shown that
virus-like particles (VLPs) composed of
GP and VP40 activate endothelial cells
that upregulate expression of intercellu-
lar adhesion molecule 1 (ICAM-1), vas-
cular cell adhesion molecule 1 (VCAM-
1), and E-selectin, which jointly results
in an increase in endothelial permeabil-
ity (7). It is also likely that the increase in
pro-inflammatory cytokines, shown exper-
imentally and in plasma samples from
patients with Ebola infection (5), con-
tribute to enhancing vasodilation and
the resulting cytokine storm (8) causes
immune dysfunction and general “shut-
down” of all immunity. Additionally, mon-
key models have shown that Ebola infec-
tion causes apoptosis in by-stander CD4
and CD8 lymphocytes and NK cells (9).
These devastating effects result in the clini-
cal symptoms of hemorrhagic lesions in the
skin, mucous membranes, visceral organs,
and large effusions in body cavities. There
is also multifocal necrosis most predomi-
nantly in the liver, spleen, kidneys, testes,
and ovaries (5).
As with all pathogens, Ebola has evolved
to evade innate immunity by hijack-
ing specific anti-viral pathways, resulting
in immunosuppression. VP35 and VP24
inhibit type I interferon activity. VP35
inhibits induction of IFN-beta produc-
tion by suppressing phosphorylation and
dimerization of IFN regulatory factor 3
(IRF-3) and enhancing SUMOylation of
IRF-7 (5, 10). Viral P24 inhibits type I
and type II IFN signaling by inhibiting
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nuclear signaling transducer ad activator of
transcription 1 (STAT 1) (10).
The combined effect of these immune
evasion strategies along with eliciting acute
immune activation, inflammation, and a
cytokine storm is lethal for the host and,
as this current epidemic has shown, more
than two-thirds of infected people with
EVD will die. Are there clues from individ-
uals who have survived EVD or properties
of the virus that can be exploited to develop
vaccine candidates?
WHAT OF IMMUNOTHERAPY?
In spite of recurrent Ebola virus outbreaks
over 38 years, immunotherapy, in the form
of passive immunization, was never really
a focus of either the research community
or of big pharma. However, about a decade
ago, the US army as well as the public health
agency of Canada realized the importance
of developing antibodies against this dev-
astating virus and therefore funded a few
research projects leading to monoclonal
antibodies.
Firstly, if we examine ZMapp, com-
prising a combination of available mon-
oclonal antibodies, i.e., c13C6 from MB-
003 and two humanized monoclonal anti-
bodies from ZMab, c2G4, and C4G7. This
product is on the market, but now in very
short supply or not at all. The antibody
combinations have proven to provide effec-
tive protection against Ebola virus in non
human primates (11, 12). MB-003, by itself,
is a cocktail of three human or human–
mouse chimeric monoclonal antibodies
c13C6, h13F6, and C6D8. This cocktail was
reported in September 2012 and tested in
Ebola-infected rhesus macaques (11, 12).
When these antibodies were provided to
experimental animals 24 or 48 h after infec-
tion, four of six macaques survived with
little viremia and only a few clinical symp-
toms. ZMab is a cocktail of three mon-
oclonal mouse antibodies: M1H3, m2G4,
and m4G7. They are directed against the
Ebola virus surface glycoprotein (EBOV-
GP). They were tested in four Ebola virus
infected macaque monkeys 48 h after infec-
tion. Two of the animals survived. The
antibodies contained in ZMapp are nowa-
days produced in the tobacco plant Nico-
tiana benthamiana, i.e., in a bioproduction
process known as “pharming.” In a process
called “rapid antibody manufacturing plat-
form” (RAMP), tobacco plants are infected
with viral vectors using Agrobacterium cul-
tures. Later, the antibodies are extracted
and purified from these plants. The com-
pany producing these antibodies is named
Kentucky BioProcessing, a subsidiary of
Reynolds American (11, 13).
Until the occurrence of the current
Ebola outbreak, ZMapp had not been used
in humans. However, in keeping with the
Animal Efficacy Rule, the FDA provided
permission to urgently treat sick people
under the organization’s expanded access
program. The accepted procedure for test-
ing safety and efficacy of drugs has so
far not been possible for this dangerous
pathogen. ZMapp was made available for
two health-care workers who were infected
by Ebola during their work in Liberia. Of
the few doses available, the two health-
care workers from the US were infused
with ZMapp serum and both survived.
Another Spanish patient died of Ebola
2 days after receiving the drug. Three more
patients were treated in Liberia of which
one died. Lastly, a British nurse with Ebola
underwent treatment in Sierra Leone and
survived the infection (14, 15).
In summary, based on these few spo-
radic cases, their heterogeneity in out-
come and adjunct therapies, the efficacy of
this drug in patients cannot be accurately
judged. In addition, ZMapp announced
that the supply of this drug had been
exhausted and so further assessment of
the efficacy of this agent was no longer
possible.
A second approach is the use of siRNA.
The FDA has allowed the RNA interference
drug known as “TKM-Ebola” for appli-
cation in patients infected with Ebola.
There is no experience in the field with
this approach, or at least none has been
reported. A Phase 1 trial in the US has
started, but was transiently placed on clini-
cal hold to further investigate a cytokine-
mediated inflammatory response in a
recipient receiving high dose TKM-Ebola.
A strategic use of passive immunother-
apy could be in post-exposure prophy-
laxis. However, as the outbreak continues
there is currently no time to conduct tra-
ditional clinical efficacy and safety studies
before use in human subjects. Regardless
of this situation, passive immunotherapy
using monoclonal antibodies warrants fur-
ther study for use in tandem with other
biomedical interventions.
Other experimental therapy approaches
include Favipiravir (T705), an anti-viral
compound currently licensed for influenza
outbreaks and brincidofovir, an experi-
mental drug developed for the treatment
of cytomegalovirus infections.
WHAT OF VACCINES?
This is the most important strategy, which
will mitigate ongoing viral transmission
(21). Although to date there are no licensed
vaccines available to prevent EVD, signif-
icant progress has been made in recent
years. The following vaccine platforms are
currently under development and have
shown promise in pre-clinical screening
against filoviruses such as Ebola virus
(EBOV) and Marburg virus (MARV):
VLPs, Venezuelan equine encephalitis virus
replicons (VEEV RP), replication com-
petent recombinant human parainfluenza
virus 3 (rHPIV3), replication incompetent
adenovirus vectors, and recombinant vesic-
ular stomatitis virus (rVSV) (16, 17). How-
ever, only the latter two vaccine platforms
are advanced enough to move into clinical
trials and will be briefly discussed herein.
Recombinant Chimpanzee Aden-
ovirus Serotype 3 Vectored Ebola Vaccine
(CAd3 Ebola vaccine) is manufactured by
Okairos/GSK (acquired by GSK in 2013).
Notably, doses that are sufficient for Phase
I clinical trials have been donated by the
Vaccine Research Center, NIAID.
The recombinant adenovirus vector
vaccine platform has been widely used
in vaccine development for a host of
infectious diseases, including HIV, malaria,
HCV, and TB. The CAd3 Ebola vaccine
is a viral vectored vaccine that expresses
the Ebola glycoprotein (GP) and is a non-
replicating vector based on an adenovirus
that primarily infects chimpanzees in the
wild. The use of a chimpanzee adenovirus
alleviates concerns about high levels of
pre-existing immunity to human aden-
oviruses that may likely reduce the immune
response to some human adenovirus-based
vaccines. There are two ChAd3 Ebola vac-
cines, one that is bivalent (against Zaire
and Sudan strains), and one that is mono-
valent (Zaire only). Only the monovalent
Zaire vaccine is currently being manufac-
tured on a larger scale. A promising study in
non-human primates (NHP) given a lethal
dose of EVD, found that CAd3 protected
all 16 animals with a single treatment.
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There is in fact already clinical trial expe-
rience in humans using this vaccine plat-
form, with the CAd3 constructs coding
for proteins against HCV and RSV, where
it has been tested in 290 people. Related
CAd63 vectors were also tested in clinical
trials against malaria in more than 1000
individuals with no serious safety con-
cerns. Phase 1 trials to assess the safety
and immunogenicity of this vaccine con-
struct have started in the US and UK in
September 2014 with a roll-out planned
for African sites (non-EVD-endemic for
Phase I) shortly. As such, implementation
of these approaches in West Africa could be
imminent.
Recombinant VSV-∆G-ZEBOV was
developed and sponsored by the Pub-
lic Health Agency of Canada and Bio-
Protection Systems Corporation (NewLink
Genetics Corporation). The rVSV platform
represents a promising vaccine candidate
approach against filoviruses (18). VSV is
a non-segmented, negative-stranded RNA
virus in the family Rhabdoviridae, which
is an animal pathogen and rarely causes
serious disease in humans. Several VSV
characteristics contribute to its favorable
profile as a vaccine vector: replication in
mammalian cell lines, growth to very high
titers, and a strong induction of innate
and adaptive (humoral as well as cellu-
lar) immune responses. This, coupled to
the very low levels of pre-existing immu-
nity to VSV in the general population,
makes such a vector attractive. Further-
more, VSV induces a neutralizing anti-
body immune response primarily directed
against the VSV glycoprotein (VSV-G), a
characteristic, which was exploited for the
design of the Ebola vaccine. The rVSV∆G-
ZEBOV vaccine consists of a recombinant
VSV, in which the G coat GP has been
deleted and substituted with Ebolavirus
Zaire envelope GP. The recombinant virus
is highly attenuated and can be grown to
high titers. The use of attenuated rVSV as a
vaccine platform against filovirus has been
demonstrated to be safe in mice and NHP.
Animals vaccinated with, rVSV-ZEBOV-
GP or rVSV-MARV-GP did not experi-
ence any major toxicity. In pre-exposure
pre-clinical studies in 20 NHP, the vac-
cine showed 100% efficacy. Post-exposure
prophylaxis led to survival of 50% of
NHP. Although clinical data in humans is
limited, the rVSV∆G-ZEBOV-GP vaccine
has been administered to a German lab-
oratory worker in the context of post-
exposure prophylaxis after Ebola expo-
sure by a needle stick injury and was
well tolerated in this setting (19). Clin-
ical trials of rVSV expressing HIV anti-
gens are currently under way. The start
of Phase 1 clinical trials to assess the
safety and immunogenicity of rVSV∆G-
ZEBOV-GP is imminent and are to be con-
ducted in US, European, and African trial
sites.
CONCLUSIONS AND THE WAY
FORWARD
The fact that the current outbreak is
through a single strain (Zaire-Ebola) and
the mutability and variability of this virus
are very low, immunotherapeutic cock-
tails and vaccine strategies should be eas-
ily achievable. Animal studies and spo-
radic clinical evidence suggest that these
approaches may be successful. The ques-
tion then becomes: how to speed up the
process? Implementation without under-
going some form of clinical safety trials is
perilous, due to the fact that not all people
infected with Ebola virus die and placing
humans at greater risk through a vaccine
would not be an option. Conversely, those
people who survive will have immunity and
could be employed to implement vaccine
cover.
This outbreak has demonstrated the
fragility of public health systems in West
African countries and breaking the human
transmission chain by immunizing large
numbers of people is ultimately going to
halt viral spread and provide protection
against future outbreaks. In line with WHO
recommendations (20), the IUIS proposes
that animal safety and immunogenicity tri-
als should be performed in parallel, and as
soon as possible, with human Phase I tri-
als with small sets of volunteers to assess
safety and to optimize dosage levels. Based
on these data, the rapid roll-out of phase
2 trial designs is warranted, allowing for
collection of further safety and immuno-
genicity data as well as early efficacy studies.
As time is not on our side, there needs to be
adequate financial support to bring vaccine
candidates to clinical trials (21) and then
a speedy implementation in African coun-
tries within a matter of weeks or months.
Although not immediately critical to halt-
ing the current outbreak – an additional
more long-term goal would be to iden-
tify the animal reservoir to prevent future
zoonotic transmission.
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